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• First reported in December 2019, the novel coronavirus named
(SARS-CoV-2), which causes the severe acute respiratory
syndrome known as COVID-19, has spread rapidly across the world.
• SARS-CoV-2 RNA has been detected not only in the respiratory
tract but also in blood, urine, and stool specimens.
• In the greater Washington, DC region (DMV), which includes parts of
Maryland and Virginia and houses the nation’s capital, there have
been 1,057,944 cases and 19,417 deaths reported since March 5
and continues to grow.
• We have established a prospective longitudinal cohort study of
patients diagnosed with COVID-19 at the George Washington
University, in Washington, DC with plans for follow-up over the
course of one year.
Goal of the biorepository:
• Collect both biospecimens and clinical data to promote scientific
inquiry into the basic science, pathogenesis, and mechanisms of the
virus causing COVID-19
Results
• The creation and establishment of a COVID-19 biorepository will 
be a valuable resource for scientific investigators to study the 
pathogenesis and mechanisms of the SARS-CoV-2 virus in the 
acute phase and longitudinally in follow-up as well as in patients 
with post acute sequelae of COVID-19. 
• Willingness of communities of color to participate in this study 
and support better understanding of COVID-19 is invaluable 
towards the study of health disparities facing this community.
• A strong participant education effort is important to coincide with 
this project, in particular, for how this contribution would support 
understanding of COVID-19, which has been a major 
motivational factor towards participation. 
• It is important to engage participants as stakeholders in the 
research process and develop processes to feedback results of 
the study to the community. 
• Study retention beyond acute enrollments has been a challenge, 
but instituting processes for improved communication including a 
variety of approaches from phone calls, messages, and e-mails, 
as well as incentives has helped improve retention. 
• Teamwork has been critical for making this bio-repository a 
success and has included collaboration across clinical, 
enrollment, abstraction, and laboratory teams as well as scientific 
investigators. 
• Establishing systems for coordination including through many 
team workers working virtually through the pandemic is important 
for a successful project. This includes establishing clear defined 
roles and virtual systems and databases that allow teams to work 
both on-site and remotely. 
92 COVID-19 PCR positive participants have been enrolled 
since April 2020 and enrollment and data collection are 
ongoing. Healthy controls are also being enrolled as a 
comparison group and 13 have been enrolled so far. An 
overview of patient enrollment according to follow-up time 
period is shown in Table 1. The enrollment, follow-up, and 
data entry process is shown in Figure 2.  
Given patient retention and data collection challenges exist, 
various approaches have been implemented to optimize data 
and specimen collection. 
Retention strategies have included:
● Verification of multiple sources of contact information at 
baseline
● Utilization of Cisco Jabber app technology to contact 
enrolled patients
● The implementation of a COVID-19 biorepository email 
account to send scheduled reminder notifications to patients
● Reimbursement by providing patients gift cards at follow-up 
visits
● Scheduling future visits during baseline
● Bolstering data collection through data extraction from 
electronic medical records
• Describe the development of the GWU COVID-19 biorepository
• Create a profile of patients enrolled during the acute phase
• Explore the value of a COVID-19 biorepository in helping answer 
important epidemiological/scientific research questions














Participant Recruitment: Confirmed SARS-CoV-2 positive patients
identified from chart review or physician referral are invited to participate
through informed signed consent under an IRB approved protocol.
Specimen Collections:
• Nasopharyngeal or oropharyngeal swabs for RT-PCR
• Serological tests from adult patients: 30mL in acute phase and 50mL
in post-acute phase including those with post-acute sequelae
• Urine studies
• Rectal, vaginal, and penile swabs are collected to detect mucosal
shedding at follow-up time points
Clinical Data:
• Clinical interviews conducted by the research team
• Chart abstractions performed
• De-identified clinical data entered into a secure RedCap database
Figure 1: COVID-19 Specimen Collection Time Points
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19 patients (N=92) 49 (53.3%) 19 (20.7%) 21 (22.8%) 3 (3.3%)
Table 1. Number of COVID-19 Patients Enrolled at Various Timepoints 
